{"id":"W4393238683","doi":"10.1016/s0140-6736(24)00319-2","title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Medical Research Council; EMD Serono; Genentech; Pfizer; Incyte; Symphogen; Alexion Pharmaceuticals; PharmaMar; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Cancer Research UK; Regeneron Pharmaceuticals; Sarcoma UK; Daiichi-Sankyo; National Institute for Health and Care Research; Amgen; Deciphera Pharmaceuticals; National Comprehensive Cancer Network; University College London Hospitals NHS Foundation Trust; Iterion Therapeutics; Exelixis; Sanofi; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Cohort; Synovial sarcoma; Population; Sarcoma; Myxoid liposarcoma; Surgery; Clinical endpoint; Oncology; Soft tissue sarcoma; Cytopenia; Liposarcoma; Clinical trial; Pathology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003559137,0.0002205171,0.0005046552,0.00007476011,0.0001465152,0.0003721717,0.0004160267,0.00006758796,0.00009484841],"category_scores_gemma":[0.00004665748,0.0001442131,0.00007014816,0.0001199626,0.00007670722,0.0002940932,0.0001510039,0.0001667708,0.00003474531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009771062,"about_ca_system_score_gemma":0.0001075782,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005172025,"about_ca_topic_score_gemma":0.00002695359,"domain_scores_codex":[0.9986396,0.00006554467,0.0002845145,0.0004507301,0.0002330933,0.0003265055],"domain_scores_gemma":[0.9988673,0.0003098422,0.00006266878,0.0005677404,0.00005560543,0.0001368112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.194345,0.02302154,0.001966345,0.0005986919,0.001676838,0.001199887,0.002005316,0.000009716152,0.04096603,0.0170979,0.05916623,0.6579465],"study_design_scores_gemma":[0.5156419,0.01191248,0.002893638,0.0004847409,0.000868378,0.0002745751,0.000299692,0.008996142,0.01074215,0.002703612,0.4445973,0.0005853816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771287,0.006401908,0.0001060053,0.009277783,0.001112721,0.002109614,0.0002921899,0.0001421827,0.003428844],"genre_scores_gemma":[0.9902028,0.001054462,0.003463662,0.001015743,0.002407419,0.000506686,0.0002331815,0.00005326861,0.001062818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6573611,"threshold_uncertainty_score":0.5880841,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1025581784956258,"score_gpt":0.4168515755341616,"score_spread":0.3142933970385358,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}